NIDA Study on Long Term Outcomes of Patients treated with Opioid Agonists/naloxone

January 7th, 2016

NIDA has released results of the first longitudinal study of patients treated with buprenorphine/naloxone (Bp/Nx) for addiction to opioid pain relievers. In the study, half reported that they were abstinent from the drugs 18 months after starting the therapy. After 3.5 years, the portion who reported being abstinent had risen further, to 61 percent, and fewer than 10 percent met diagnostic criteria for dependence on the drugs.

The study also identified factors that influence the odds of recovery. The findings indicate that two factors strongly influence patients’ chances for recovery from addiction to pain relievers:

  • At each follow-up, patients who told interviewers that they were currently engaged in opioid agonist therapy were much more likely to report that they were abstinent than those who were not using the medications.
  • Patients who had ever used heroin had poorer odds of overcoming their pain reliever addiction than those who had never done so.

“Our findings are cause for optimism for these specific patients,” says Dr. Roger Weiss, of McLean Hospital and Harvard Medical School, who co-led the study.

View the abstract for the artice in Drug and Alcohol Dependence

View the NIDA article

Posted in Content

A Project of the Governor's Institute on Alcohol & Substance Abuse and the North Carolina Society of Addiction Medicine.
Funded wholly or in part by the federal Substance Abuse Prevention and Treatment Block Grant Fund (CFDA #93.959) as a project of the NC Division of Mental Health, Developmental Disabilities & Substance Abuse Services.